文献速递前列腺癌

扩展家族史定义对前列腺癌主动监测结局的影响

Impact of an Expanded Definition of Family History on Outcomes of Active Surveillance for Prostate Cancer.
PubMed 文献 · J Urol · 2023-03-09

在麻省总医院1997—2019年接受主动监测的855例前列腺癌患者中,300例(35.1%)有前列腺癌家族史,95例(11.1%)有提示遗传性癌症综合征的相关恶性肿瘤家族史;提示遗传性癌症综合征的家族史是多变量分析中活检进展的独立预测因素(HR 1.43,95%CI 1.01-2.02),并与更短的治疗无生存期相关(HR 1.58,95%CI 1.14-2.18)。

要点

  • 855例中300例(35.1%)有前列腺癌家族史,95例(11.1%)有提示遗传性癌症综合征的家族史。
  • 仅前列腺癌家族史与活检进展无关,提示遗传性癌症综合征的家族史与活检进展风险升高相关(HR 1.43)。
  • 此类家族史者仍可接受主动监测,但应告知疾病进展风险较高。

核心结论

  • 提示遗传性癌症综合征的扩展家族史是主动监测期间活检进展的独立预测因素。
  • 有此类家族史的男性仍可接受主动监测,但应告知疾病进展风险较高。

研究设计与样本

  • 研究纳入1997—2019年在麻省总医院接受前列腺癌主动监测且具有详细家族癌症史数据的患者。
  • 主要结局为活检无进展生存期,次要结局为治疗无生存期、前列腺切除术中的不良病理特征及治疗后的生化复发。
  • 统计分析采用Kaplan-Meier法和Cox回归。

主要发现

  • 855例可评估患者中,300例(35.1%)有前列腺癌家族史,95例(11.1%)有提示遗传性癌症综合征的相关恶性肿瘤家族史。
  • 仅前列腺癌家族史与活检进展无关,而提示遗传性癌症综合征的家族史与活检进展风险显著升高相关(HR 1.43,95%CI 1.01-2.02),多变量分析中独立于其他已知临床病理危险因素。
  • 多变量分析中,提示遗传性癌症综合征的家族史与显著更低的治疗无生存期相关(HR 1.58,95%CI 1.14-2.18)。
  • 家族史与手术病理不良特征或生化复发之间未发现显著关联。

临床怎么用

  • 作者认为,有提示遗传性癌症综合征家族史的男性仍可接受主动监测,但应告知其疾病进展风险较高。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Despite family history being an established risk factor for prostate cancer, the role of a broader definition of family history inclusive of not just prostate cancer but other genetically related malignancies has not been investigated in the active surveillance population. Here, we evaluate the impact of an expanded definition of family history on active surveillance outcomes. MATERIALS AND METHODS: Patients undergoing active surveillance for prostate cancer at Massachusetts General Hospital from 1997-2019 with detailed data available on family cancer history were identified. Primary outcome was biopsy progression-free survival, and secondary outcomes were treatment-free survival, adverse pathological features at prostatectomy, and biochemical recurrence after treatment. Statistical analyses were conducted using the Kaplan-Meier method and Cox regression. RESULTS: Among 855 evaluable patients, 300 (35.1%) patients had any family history of prostate cancer, and 95 (11.1%) had a family history of related malignancies suggestive of a hereditary cancer syndrome. Family history of prostate cancer alone was not associated with biopsy progression, whereas family history suggestive of a hereditary cancer syndrome was associated with a significantly increased risk of biopsy progression (HR 1.43, 95%CI 1.01-2.02), independent of other known clinicopathological risk factors in multivariable analysis. Similarly, family history suggestive of a hereditary cancer syndrome was associated with significantly lower treatment-free survival (HR 1.58, 95%CI 1.14-2.18) in multivariable analysis. No significant association was found between family history and adverse features on surgical pathology or biochemical recurrence. CONCLUSIONS: An expanded family history suggestive of a hereditary cancer syndrome is an independent predictor of biopsy progression during active surveillance. Men with such a family history may still be offered active surveillance but should be counseled regarding the higher risk of disease progression.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Schneider AC, Chandrasekar T, Bowler N, et al. Impact of an Expanded Definition of Family History on Outcomes of Active Surveillance for Prostate Cancer. J Urol. 2023. PMID: 36951811. doi:10.1097/JU.0000000000003396

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。